B+
Bull case
25%
Probability
Target price
$24.00
Analysis reference price unavailable
Analysis 2026-09-10 · RankAlpha Sentiment Codex
NTLA
Intellia TherapeuticsANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The thesis has strengthened materially: FDA acceptance and Priority Review create a defined regulatory milestone, while HAELO's strong efficacy supports a potentially differentiated one-time therapy. Intellia also reported approximately $628 million in cash, cash equivalents, and marketable securities at Q2 end, expected to fund operations at least into 2028 [#SEC-8K-2026-08-06].
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +8.6.
What can break
Clinical, safety, manufacturing, labeling, reimbursement, or commercial-launch issues could reduce the value of lonvo-z.
Momentum
39
Value
41
Sentiment
100
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $15.50 · Bull $24.00 · Bear $7.50Analysis 2026-09-10; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-11 • Model: HYBRID_IC_RP
AI Memo
As of 2026-09-10 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-11
Investment thesis
As of 2026-09-11
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-11. Definitions
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $23.81
Why
Momentum39 · Δ7d +8.6
Value41 · Δ7d -0.0
Sentiment100 · Δ7d +8.6
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +8.6.
Contradictions & invalidation
- • Clinical, safety, manufacturing, labeling, reimbursement, or commercial-launch issues could reduce the value of lonvo-z.
- • Continued cash burn could create future financing or dilution risk if development or launch costs exceed expectations.
- • The company remains dependent on successful lonvo-z approval, manufacturing readiness, safety monitoring, reimbursement, and commercial adoption.
Catalyst clock
2026-12-31
nex-z Phase 3 execution and enrollment progress
Lead driver: Sentiment · See AI snapshot
Momentum
39
9% active weight
Current posture
7d trendImproving
Δ7d
+8.6
Δ21d
+25.0
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.1
Sentiment
100
62% active weight
Current posture
7d trendImproving
Δ7d
+8.6
Δ21d
+7.7
Why this grade
Composite grade A. Momentum 38.9 / Value 41.2 / Sentiment 100.0
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-09-10. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$15.50
Analysis reference price unavailable
Analysis 2026-09-10 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$7.50
Analysis reference price unavailable
Analysis 2026-09-10 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$1.69B
Beta
2.09
Shares Out
140.13M
P/E (TTM) · Derived
-3.2
P/S (TTM)
18.87
P/FCF (TTM) · Derived
-4.13
Rev YoY
-46.2%
EPS YoY
-18.2%
Gross Margin
+74.4%
Op Margin
-711.7%
Net Debt
-$356.56M
Current Ratio
6.65
As of 2026-09-11 • Updated nightlySource: Internal modelMethods & Data